Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R43/R44 – Clinical Trial Optional)

0
16

Funding Opportunity ID:309081
Opportunity Number:RFA-DA-19-014
Opportunity Title:Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R43/R44 – Clinical Trial Optional)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Grant
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.279
Eligible Applicants:Small businesses
Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Sep 18, 2018
Close Date:Dec 14, 2018
Last Updated Date:Sep 19, 2018
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:The purpose of this Funding Opportunity Announcement is to develop and evaluate the loyalty/reward-based digital technologies (e.g., mobile medical app/device platforms and other digital technologies) to be used as a combination product to increase medication adherence. The objective of Phase I (R43) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the reward-based platform in a larger sample. The primary endpoint is adherence to FDA-approved medications for substance use disorders. Rewards and contingencies should be delivered in a self-sustaining manner and include a front-end interface allowing treatment providers to monitor progress and deliver rewards. Platforms may include novel features including, but not limited to, automated tracking tools, real-time assessments of patient progress, medication intake, and momentary assessment. Data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA cleared device.
Version:1





Visit the Official Webpage For More Details on Loyalty and Reward-Based Technologies to Increase Adherence to Substance Use Disorder Pharmacotherapies (R43/R44 – Clinical Trial Optional)